Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06516952 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
A Phase 3 study of Prurigo Nodularis, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
- 20
- Study locations
NCT06516952 is a Phase 3 study of Prurigo Nodularis that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 330 participants, above the 206-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (60% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT06516952, a Phase 3 study of Prurigo Nodularis, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Povorcitinib
Study Locations (20)
Florida
- Rendon Center the Dermatology and Aesthetic Center - Boca Raton
- Driven Research Llc - Coral Gables
- University of Miami Miller School of Medicine - Miami
- Research Institute of the Southeast, Llc - West Palm Beach
Illinois
- Illinois Dermatology Institute the Chicago Loop - Chicago
- Chicago Cosmetic Surgery and Dermatology - Chicago
- Center For Medical Dermatology and Immunology Research - Chicago
- Northshore University Healthsystem - Skokie
Michigan
- Oakland Hills Dermatology - Auburn Hills
- Hamzavi Dermatology - Fort Gratiot
- Somerset Skin Centre - Troy
Arkansas
- Premier Dermatology Clinical Trials Institute At Northwest Arkansas - Fayetteville
- Burke Pharmaceutical Research - Hot Springs
California
- Dermatology Research Associates - Los Angeles
- Northridge - Northridge
Missouri
- Medisearch Clinical Trials - Saint Joseph
- Washington University School of Medicine - St Louis
Alabama
- Cahaba Dermatology - Birmingham
Arizona
- Banner - University Medicine Multispecialty Services Clinic - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2027-05-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06516952
The ClinicalTrials.gov registry entry for NCT06516952 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 206-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (60% higher). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06516952 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT06516952 about?
NCT06516952 is a clinical study titled "A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)". The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
What is the current status of trial NCT06516952?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2024-10-10. Estimated completion is 2027-05-03.
What conditions does trial NCT06516952 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
What interventions are being tested in trial NCT06516952?
The interventions under investigation include: Placebo (DRUG), Povorcitinib (DRUG).
Who is sponsoring clinical trial NCT06516952?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06516952 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
ACTIVE NOT RECRUITING · Phase 3
-
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
COMPLETED · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.